Regulation · United Kingdom

Is MOTS-c legal
in the UK?

We found no UK law that names MOTS-c. Whether a product containing it may be sold turns on medicines law, which the MHRA applies product by product. Here are the provisions, what UK bodies have said, and the 2026 record.

Short answerRegulation · 7 min read · Updated 18 Nov 2026

We found no UK marketing authorisation for MOTS-c and no UK law that names it. Medicines law treats a product as a medicine if it is presented as treating disease or used to change how the body works, and selling, supplying or advertising one without authorisation is an offence. The MHRA says it disregards “research purposes” claims used to avoid that law.

Key takeaways

  • We found no UK legislation that names MOTS-c, and the emc, the UK database of licensed medicines’ product information, returned no product containing it (18 Nov 2026).
  • Selling or supplying an unauthorised medicinal product is an offence under the Human Medicines Regulations 2012, with a maximum of two years’ imprisonment, a fine or both on indictment.
  • The MHRA classifies finished products, not substances, and told STV News in March 2026 that it disregards “research purposes” claims used to avoid medicines law.
  • MOTS-c is not listed in Schedule 2 to the Misuse of Drugs Act 1971; whether a product is a medicine is a separate question.
  • In UK sport, WADA names MOTS-c in class S4.4.1, prohibited at all times; UK Anti-Doping called the 2025 List’s new examples “additional examples of substances that are already prohibited”.

01What does UK law say about MOTS-c?

UK medicines law keeps no list of peptides. It asks what a product is, and then who may sell, supply or advertise it. We found no UK legislation that names MOTS-c.

Is the product a medicine? Regulation 2 of the Human Medicines Regulations 2012 has two limbs. A product is a medicinal product if it is “presented as having properties of preventing or treating disease in human beings”. It is also one if it “may be used by or administered to human beings” to restore, correct or modify a physiological function “by exerting a pharmacological, immunological or metabolic action”. Either limb is enough.

What follows if it is. Regulation 46(1) says: “A person may not sell or supply, or offer to sell or supply, an unauthorised medicinal product.” Regulation 46(4) and (5) also bar manufacturing or assembling one, or procuring its sale, supply, manufacture or assembly, where the person knows or has reasonable cause to believe it is to be sold or supplied in breach of 46(1). Regulation 47 makes a breach an offence, punishable on indictment by “a fine, to imprisonment not exceeding two years or to both”.

Advertising. Regulation 279 says a person “may not publish an advertisement in Great Britain for a medicinal product” unless a UK marketing authorisation, a temporary authorisation, a certificate of registration or a traditional herbal registration is in force for it. Regulation 303 makes a breach an offence, with the same two-year maximum on indictment.

The narrow exception. Regulation 167 covers “specials”: products made to a prescriber’s specification, in response to an unsolicited order, for the special needs of a patient that prescriber is directly responsible for, and never advertised. It serves one patient at a time; it is not a route to a market.

ProvisionWhat it coversMaximum on indictment
Human Medicines Regulations 2012, reg 2Defines a medicinal product, by presentation or by functionDefinition only
Reg 46(1)Selling or supplying, or offering to, an unauthorised medicinal product2 years, a fine or both (reg 47)
Reg 46(4) and (5)Manufacturing, assembling or procuring the sale of one meant for sale in breach of 46(1)2 years, a fine or both (reg 47)
Reg 279Advertising a medicinal product with no UK authorisation in force2 years, a fine or both (reg 303)
Reg 167Specials for an individual patient, made to a prescriber’s specification, unadvertisedAn exception, not an offence
Misuse of Drugs Act 1971, Sch 2Controlled drugs, Classes A to CMOTS-c is not listed

02How would the MHRA decide whether a MOTS-c product is a medicine?

Product by product. The MHRA’s Guidance Note 8 says: “The MHRA only classifies finished products and not individual substances and ingredients.”

The guidance lists what the MHRA weighs. Among the factors are the ingredients’ pharmacological, immunological or metabolic properties, the product form (“capsule, tablet, injection, etc.”) and the way it is to be used, the product literature, and “the risks which use of the product may pose.” Among the kinds of marketing that it says may suggest a medicine are “references to medical conditions” and “references to medical and / or clinical research and testing”.

For the function limb, the guidance quotes the European Court of Justice: the authorities “must decide on a case-by-case basis, taking account of all the characteristics of the product, in particular its composition, its pharmacological, immunological or metabolic properties”. The MHRA’s borderline-products guidance, updated on 2 July 2026, adds how a product “is presented to the public through labelling, packaging, promotional literature, advertisements, websites, social media and customer reviews”.

Research labels. In a statement to STV News in March 2026, the MHRA’s head of borderlines said the agency disregards “research purposes” claims “if it is clear that such claims are being used as an attempt to avoid medicines regulations.” The statement went on: “If a product is classified as a medicine and is not appropriately authorised, we take regulatory compliance action, including the removal of the product from the UK market where necessary.” It did not name MOTS-c. More on labels: what “research use only” means.

Is any MOTS-c product licensed? We found none. On 18 November 2026 the emc, the UK database of licensed medicines’ product information, returned “No search results” for “MOTS-c”, “MOTS c” and “mitochondrial open reading frame”; the same search for somatropin returned 21. The European Medicines Agency’s medicines data export of the same day has no MOTS-c entry. In a 2026 briefing, FDA staff also reported that the EMA “did not list any products containing MOTS-c or MOTS-c acetate that are authorized for use.” We could not run the MHRA Products search, which needs a browser.

03What have UK authorities done, and when?

A dated record, from the sports listing to the 2026 enforcement wave. None of the MHRA documents below names MOTS-c. Press reports are marked.

DateWhoWhat happened
25 Sep 2024WADAPublishes the 2025 Prohibited List, which adds MOTS-c by name as an example in class S4.4.1; UK Anti-Doping called that year’s new examples substances “already prohibited”
1 Jan 2025WADAThe 2025 List takes effect, in UK sport as everywhere the Code applies
25 Feb 2026MHRA Criminal Enforcement UnitAnnounces raids on a farm near Sleaford and a residential address in Grantham, believed to be used to make and distribute unlicensed weight-loss medicines “as well as peptide products”
19 Mar 2026MHRA, statement to STV News (press report)Says it disregards “research purposes” claims used to avoid medicines regulations
12 May 2026MHRAReplaces Guidance Note 8 with an amended version
28 May 2026MHRA Criminal Enforcement UnitRaids an estate near Northampton believed to make and distribute unlicensed weight-loss medicines “as well as peptide products”; two arrests
2 Jul 2026MHRAUpdates its borderline-products guidance
18 Nov 2026Our checkNo UK legislation, no product on the emc and no published MHRA determination naming MOTS-c found

The two MHRA press releases describe “peptide products” without naming compounds. They show where enforcement has been aimed: unlicensed manufacture and supply, with peptides alongside weight-loss drugs.

04Is MOTS-c a controlled drug in the UK?

No. MOTS-c is not listed in Schedule 2 to the Misuse of Drugs Act 1971, which sets out Classes A, B and C. We read the revised schedule on legislation.gov.uk on 18 November 2026. The peptide hormones that are controlled there, such as somatropin, sit in Class C.

Not being a controlled drug does not settle the medicines question above. The two regimes are separate. The wider picture, including growth hormone and the Psychoactive Substances Act 2016, is on are peptides legal in the UK?

05How is MOTS-c treated in UK sport?

UK sport follows the World Anti-Doping Code. WADA’s Prohibited List names MOTS-c in class S4.4.1, metabolic modulators, among activators of the AMP-activated protein kinase (AMPK). The class is prohibited in and out of competition, and the List says substances in S4.4 are non-Specified Substances, a status that bears on the length of a sanction.

WADA first named MOTS-c in the 2025 List. UK Anti-Doping’s summary of that List gave it as one of the year’s new examples and said: “Please note that these are not new substances being added to the 2025 List for the first time but are additional examples of substances that are already prohibited.” Detail: is MOTS-c banned in sport?

06What changed in 2026?

The law did not change. Enforcement and guidance did.

No new UK law. On 18 November 2026 a legislation.gov.uk full-text search for “MOTS-c”, and phrase searches for “MOTS c” and “mitochondrial open reading frame”, returned no results. The same search for somatropin returned 30.

More enforcement. The MHRA’s Criminal Enforcement Unit announced raids in February and May on premises it believed were used to make and distribute unlicensed weight-loss medicines and peptide products.

Updated guidance. Guidance Note 8 was amended in May and the borderline guidance updated in July.

Outside the UK. The US HHS policy of October 2026, which names MOTS-c, is a draft enforcement policy on compounding by licensed US pharmacies, federal facilities and physicians, and it is not an approval: is MOTS-c legal in the US?

07What we don’t know

How the MHRA would classify a given product. It decides finished products case by case. We found no published MHRA determination naming MOTS-c in its final determinations (to December 2023) or its regulation 165 notices (October 2019 to May 2023).

MHRA Products. We could not run its search. Our check for a licensed UK product is the emc result above.

Northern Ireland. Parts of these rules differ there, and we have not covered them.

The evidence on MOTS-c itself is in our MOTS-c research guide and in MOTS-c claims and the evidence. Changes are logged in our regulatory changelog.

This is a plain-English summary of public documents, checked on 18 Nov 2026. It is not legal advice.

RefSources

  1. The Human Medicines Regulations 2012 (SI 2012/1916), regulations 2, 46, 47 and 167. UK legislation, revised text (data.xml); read 18 Nov 2026. www.legislation.gov.uk/uksi/2012/1916/regulation/46
  2. The Human Medicines Regulations 2012 (SI 2012/1916), regulations 279 and 303 (advertising). UK legislation, revised text; read 18 Nov 2026. www.legislation.gov.uk/uksi/2012/1916/regulation/279
  3. MHRA. Guidance Note 8: A guide to what is a medicinal product, pp. 9, 12. Guidance; the document says “Published September 2025” and was replaced with an amended version on 12 May 2026; read 18 Nov 2026. assets.publishing.service.gov.uk/media/6a747082bde92a23046b2…
  4. MHRA. Borderline products: how to tell if your product is a medicine. Guidance, updated 2 Jul 2026 (change history includes the GN8 replacement of 12 May 2026); its attached final determinations (December 2023) and regulation 165 notices (October 2019 to May 2023) searched for “MOTS”; read 18 Nov 2026. www.gov.uk/guidance/borderline-products-how-to-tell-if-your-…
  5. Misuse of Drugs Act 1971, Schedule 2 (Classes A, B and C). UK legislation, revised text; read 18 Nov 2026. www.legislation.gov.uk/ukpga/1971/38/schedule/2
  6. MHRA. MHRA disrupts second manufacturing facility suspected to be involved in the manufacture of illegal weight loss medicines in latest blow to criminal network. Press release, 25 Feb 2026. www.gov.uk/government/news/mhra-disrupts-second-manufacturin…
  7. MHRA. Two arrested during the MHRA’s largest ever seizure of unlicensed weight loss medicines. Press release, 29 May 2026 (raid on 28 May 2026). www.gov.uk/government/news/two-arrested-during-the-mhras-lar…
  8. Flett A. The peptide boom (MHRA statement, Lynda Scammell, head of borderlines). STV News, 19 Mar 2026. Press report of an MHRA statement; read 18 Nov 2026. news.stv.tv/scotland/the-peptide-boom-call-for-review-of-leg…
  9. emc (electronic medicines compendium). Searches for “MOTS-c”, “MOTS c” and “mitochondrial open reading frame” (control: “somatropin”). Database searches, 18 Nov 2026. www.medicines.org.uk/emc/search?q=MOTS-c
  10. legislation.gov.uk. Full-text search for “MOTS-c”; phrase searches for “MOTS c” and “mitochondrial open reading frame” (control: “somatropin”). Database searches, 18 Nov 2026. www.legislation.gov.uk/all?text=MOTS-c
  11. European Medicines Agency. Medicines data export (JSON; 2,765 records, timestamp 18 Nov 2026), searched for “MOTS”. Dataset, 18 Nov 2026. www.ema.europa.eu/en/documents/report/medicines-output-medic…
  12. U.S. Food and Drug Administration. FDA briefing document, Pharmacy Compounding Advisory Committee, 23–24 July 2026: MOTS-c-related bulk drug substances, p. 21. Advisory committee briefing, 2026; read 18 Nov 2026. www.fda.gov/media/193347/download
  13. World Anti-Doping Agency. The Prohibited List 2025, 2026 and 2027, class S4 (S4.4.1). International Standard (2026 List in force since 1 Jan 2026; 2027 List takes effect 1 Jan 2027); read 18 Nov 2026. www.wada-ama.org/en/prohibited-list
  14. UK Anti-Doping. 2025 Prohibited List: Summary of Changes. News page, undated in its text (it describes the 2025 List, published 25 Sep 2024); read 18 Nov 2026. www.ukad.org.uk/news/2025-prohibited-list-summary-changes

Plain-English summary of public sources, not legal or medical advice. Last checked 18 Nov 2026.

Questions

Is MOTS-c a licensed medicine in the UK?

Not that we found. The emc returned no product containing it on 18 November 2026, and FDA staff found no MOTS-c product authorised by the European Medicines Agency. We could not run the MHRA’s own product search.

Has the MHRA ruled on MOTS-c?

We found no published MHRA determination naming MOTS-c. The MHRA classifies finished products, not substances, so any decision would concern a specific product and how it is presented and used.

Does a “research use only” label change how UK law treats a MOTS-c product?

Not by itself. The MHRA told STV News in March 2026 that it disregards “research purposes” claims used to avoid medicines regulations, and its guidance weighs claims, composition, form and use together.

Is MOTS-c a controlled drug in the UK?

No. It is not listed in Schedule 2 to the Misuse of Drugs Act 1971. Whether a product is a medicine is decided separately, under the Human Medicines Regulations 2012.

Is MOTS-c prohibited in UK sport?

Yes. UK sport applies the WADA Prohibited List, which names MOTS-c in class S4.4.1, metabolic modulators, prohibited in and out of competition.

Evidence before hype.

One email a week: new research explained and regulatory changes. No prices, no hype.

Get the 6:00 brief

Free. Unsubscribe any time.

Written by 6AM Research. Drafted from primary sources; every claim links to its source, and the page is dated. Editorial policy · How we check every page